Janssen reports positive data from long-term study of Imbruvica

Janssen has announced new phase III clinical trial data that demonstrates the long-term benefits offered by its cancer drug Imbruvica.

Follow-up generated over four years from the pivotal RESONATE trial showed that the ibrutinib-based therapy offered significant advantages in the treatment of relapsed and refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma.

At a median follow-up of 44 months, Imbruvica was associated with a three-year progression-free survival rate of 59 percent, compared to three percent for ofatumumab.

These benefits were observed across all baseline disease and patient characteristics, particularly among patients with genetic mutation deletion 11q, a prognostic feature usually associated with an increased risk of poor outcomes.

With this longer follow-up data, the overall response rate for the drug reached 91 percent, with a complete response of nine percent.

Dr Peter Lebowitz, global oncology head at Janssen, said: "With more than four years of follow-up, we continue to be impressed with the durability and control by ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.